Recent Company News

• 11:00 PM ET Jul 20, 2025
  

  Sun Pharmaceutical Industries phase 3 clinical studies evaluating Tildrakizumab 100 mg (ILUMYA) in active psoriatic arthritis meets primary endpoint (INR 1693.25, 0.00)

• 08:00 AM ET Jul 02, 2025
  

  Hikma receives FDA approval for TYZAVAN" (Vancomycin Injection, USP) in the US

• 04:06 AM ET Jul 02, 2025
  

  Hikma Pharmaceuticals announced the approval of a novel formulation of the first-of-its-kind, ready-to-infuse formulation of vancomycin, under the brand name TYZAVANTM by the FDA. (1990.0000p, -2)

• 07:15 AM ET Jun 30, 2025
  

  Hikma Pharmaceuticals publishes its 2024 Sustainability Report (2020.0000p, -6)

• 12:28 PM ET Jun 28, 2025
  

  Hikma Pharmaceuticals announces $1B investment by 2030 to further expand its US manufacturing and R&D capabilities (2026.0000p, 0)

• 11:00 AM ET Jun 28, 2025
  

  Hikma Pharmaceuticals USA announces $1 Billion of new US investment to further expand its domestic manufacturing and development of essential generic medicines

• 04:09 AM ET Jun 25, 2025
  

  Hikma launches Methylene Blue Injection USP in the US (2058.0000p, -4)

• 02:32 AM ET Jun 09, 2025
  

  Hikma Pharmaceuticals reinstated neutral at BofA (2128.0000p, 0)

• 04:07 AM ET Jun 05, 2025
  

  Hikma Pharmaceuticals launches Triamcinolone Acetonide Injectable Suspension, USP, in the US (2100.0000p, 0)

• 09:31 PM ET Jun 02, 2025
  

  RemeGen presents results of Phase 2 study evaluating efficacy and safety of disitamab vedotin as first-line therapy for HER2-expressing (la/m) gastric cancer (HK$48.20, 0.00)